Artiva Biotherapeutics (ARTV) Capital Leases (2024 - 2025)

Artiva Biotherapeutics' (ARTV) quarterly Capital Leases came in at $11000.0 in Q1 2025, down 75.0% on a QoQ basis from $44000.0 in Q4 2024.

Artiva Biotherapeutics (ARTV) Capital Leases (2024 - 2025) Analysis & Trends

Artiva Biotherapeutics (ARTV) has 2 years of Capital Leases data on file, last reported at $11000.0 in Q1 2025.

On a quarterly basis, Capital Leases changed N/A year-over-year to $11000.0 in Q1 2025; TTM through Mar 2025 was $11000.0, a N/A change from a year earlier, with the FY2024 full-year figure at $44000.0, changed N/A from the prior year.
Capital Leases for Q1 2025 stood at $11000.0, down from $44000.0 in the prior quarter.
Over the last five years, Capital Leases for ARTV reached as high as $106000.0 in Q2 2024 and fell as low as $11000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Artiva Biotherapeutics	249.99 Mn	249.99 Mn	-

Download Data